

Date of preparation: June 2022

Yvonne Saenger, MD
215 West 91st St #42
New York, NY 10024
646-425-5734
yvonne.saenger@einsteinmed.edu

Place of Birth: Chicago, IL

Citizenship: USA

EDUCATION

9/1992 – 6/1996	Harvard University, Harvard and Radcliffe College BA magna cum laude in Russian Literature, May 1996	Cambridge MA
8/1996 – 5/2001	Columbia University, College of Physicians & Surgeons MD, May 2001	New York, NY

TRAINING

7/2001 – 7/2002	Department of Medicine, Columbia University Medicine Intern	New York, NY
7/2002 – 7/2004	Department of Medicine, Columbia University Medicine Resident	New York, NY
7/2004 – 7/2008	Memorial Sloan Kettering Cancer Center Hematology and Oncology Fellow	New York, NY
7/2006 – 7/2008	Memorial Sloan Kettering Cancer Center K12 Fellow in translational oncology research	New York, NY
7/2005 – 7/2008	Memorial Sloan Kettering Cancer Center Research Fellow, laboratory of Jedd Wolchok and Alan Houghton	New York, NY
7/2008 – 7/2009	Johns Hopkins University Medical Center Research Fellow, laboratory of Elizabeth Jaffee MD	Baltimore, MD

PROFESSIONAL EMPLOYMENT AND HOSPITAL APPOINTMENTS

8/2009 – 7/2014	Icahn School of Medicine at Mount Sinai Assistant Professor of Medicine at ISMMS	New York, NY
8/2009 – 7/2014	Mount Sinai Medical Center Attending, Medical Oncology	New York, NY
8/2014 -7/2019	Columbia University College of Physicians & Surgeons Assistant Professor of Medicine, Division of Hematology& Oncology	New York, NY

8/2014 -9/2021	New York-Presbyterian/Columbia University Medical Center Attending, Medical Oncology	New York, NY
7/2019- 9/2021	Columbia University College of Physicians & Surgeons Associate Professor of Medicine, Division of Hematology & Oncology Director, Melanoma Immunotherapy Co-Director, Human Immune Monitoring Core	New York, NY
9/2021- present	Albert Einstein College of Medicine/Montefiore Associate Professor of Medicine, Division of Hematology & Oncology, Microbiology & Immunology, and Pathology Co-Leader of the Albert Einstein Cancer Center Cancer Therapeutics Program. Director of the Albert Einstein Cancer Center and Montefiore Cancer Immunotherapy Program Director, Human Immune Monitoring Core Attending, Medical Oncology	New York, NY

LICENSURE AND BOARD CERTIFICATION

2004 – present	New York State License #229942
2005 – present	Internal Medicine Board Certified
2007 – present	Medical Oncology Board Certified

HONORS AND AWARDS

2018	Irving Scholar Award, Herbert Irving Medical Center
2015- 2017	Cancer Clinical Investigator Team Leadership Award
2015	Immunotherapy Pioneer, <i>The Scientist</i> Magazine
2014	American Association for Cancer Research Innovator Award
2006	AACR/ASCO methods in clinical cancer research award
1998	Dean's Day Award for Medical Student Research
1996	Harvard University Senior Thesis Award, Slavic Languages and Literatures
1996	Harvard University- Dean's list and Harvard College award

ACADEMIC SERVICE

2021- present	Faculty Director, Human Immune Monitoring Core at Albert Einstein
2016- 2021	Faculty Co-Director, Human Immune Monitoring Core at CUMC
2019- 2021.	Standing Member Course Director, Hematology/Oncology Sub-Internship

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

FEDERAL SVCE

2022	Reviewer, NCI CCSG, UH2/UH3 R01, R21 and R03 awards, NCI
2021	Reviewer, UH2/UH3 awards, NCI
2021	Reviewer, Cancer Nanotechnology Study Section, R01 grants, NCI
2020	Reviewer, Cancer Nanotechnology Study Section, R01 grants, NCI
2020	Reviewer, Melanoma and Pancreas Spore, NCI, NIH
2019	Reviewer, Melanoma Program, DOD
2019	Provocative Questions Development Panel, NCI, NIH
2018	Reviewer, Department of Defense Career Development Awards in Skin Cancer
2018	FDA Consultant Panel on Intra-Tumor Therapy

2018	Reviewer, R21 and R03 grants, NCI, Clinical and Translational Exploratory/Developmental
2018	Reviewer, Melanoma Program, DOD
2017	Reviewer, Special Emphasis Panel R21 awards, NCI, NIH
2012	Reviewer and study section member, Cancer Prevention R03 and R21 awards, NCI NIH

MEMBERSHIPS

2014- present	Member and <u>Awardee</u> , Melanoma Research Alliance
2013- present	Member, Melanoma Committee, Eastern Cooperative Oncology Group
2013- present	Member, <u>Speaker</u> (2013, 2018-2020), and <u>Organizer</u> for Annual Meeting for Society for the Immunotherapy of Cancer (2020-2021)
2008- present	Member, American Association of Clinical Oncology
2005- present	Member, American Association for Cancer Research

JOURNAL REVIEW

2015-2021	<i>Journal of Clinical Oncology</i>
2017-2022, 2015	<i>Clinical Cancer Research</i>
2018-2021	<i>Journal for the Immunotherapy of Cancer</i>
2020	<i>Journal of Clinical Investigation</i>
2019, 2014-2017	<i>Journal of Investigative Dermatology</i>
2018-2020, 2015	<i>Cancer Immunology Research</i>
2019	<i>Scientific Reports</i>
2018-2019	<i>Cancer Prevention Research</i>
2018-1019	<i>Cancer Letters</i>
2018	<i>Tumori Journal</i>
2016	<i>Cancer</i>
2016	<i>Cancer Immunology and Immunotherapy</i>
2016	<i>JAMA</i>
2015	<i>Cancer Research</i>
2015	<i>Pigment Cell and Melanoma Research</i>
2015, 2008	<i>Oncotarget</i>
2013, 2009	<i>Expert Opinion in Biologic Therapy</i>
2012	<i>Investigational New Drugs</i>
2008	<i>Oncotarget</i>

JOURNAL EDITOR

2017	<i>Cancer Convergence, Nature Publications</i>
2015	<i>Seminars in Oncology</i>

GRANT SUPPORT

1R01CA260375 Applying pathomics to establish a biosignature for aggressive skin melanoma.

Role: Contact PI

Sponsoring Agency: NCI

Performance Period: 05/01/2021- 04/30/2026

\$434,130 direct funds/year

UH3 CA218149-01A1 A prognostic mRNA immune signature for resected stage II-III melanoma

Role: **Contact PI**

Sponsoring Agency: NCI.

250,000/year x 3 years direct funds/year 2021-2024

R01-FDA 006108 Phase 1 Study of Talimogene Laherparepvec for the Treatment for Advanced Pancreatic Cancer

Role: **Contact PI**

Sponsoring Agency: FDA

Performance Period: 08/01/18-08/01/22

250,000/year x 3 years- in no cost extension

PAST SUPPORT

- 2019-2021 UH2 CA218149-01A1 A prognostic mRNA immune signature for resected stage II-III melanoma (Saenger) Sponsor: NCI, NIH
- 2019-2021 Development of predictive biomarkers for response to immunotherapy in melanoma using clinical grade formalin fixed paraffin embedded (FFPE) tissues (Saenger) Sponsor: Regeneron
- 2017- 2021 Establishing a prognostic immune signature in early stage melanoma (Saenger)
Sponsor: Irving Institute, CUMC
- 2016-2021 R01CA205426 Elucidating genetics of response to ICB in lung cancer (Rizvi)
Sponsor: NCI, NIH
- 2016 - 2019 Defining biomarkers of immune activation during anti-PD1+Tvec therapy (Saenger)
Sponsor- Melanoma Research Alliance
- 2016 - 2018 Efficacy of INT230-6 combined with immunotherapy in a melanoma mouse model (Saenger)
Sponsor- Intensity Therapeutics Inc.
- 2017 - 2018 Impact of Zyclara on Immune Micro-Environment in Acinic Keratosis (Goldenberg) Co-I
Sponsor: Valeant
- 2015 - 2018 R01FD005109 Phase II trial of ADXS11-001 vaccine for HPV-related oropharyngeal cancer (Sikora) Co-I Sponsor: FDA/Baylor College of Medicine
- 2015 - 2018 Establishing Efficacy And Mechanisms of Talimogene Laherparepvec Combined with Anti PD-1 and Braf Inhibition in Spontaneous Murine Melanoma (Saenger) Sponsor: Amgen
- 2014 - 2016 Proving Immune Signatures in High Risk Primary Melanoma Tumors to Establish Prognostic Biomarkers and Mechanisms of Successful Immune Surveillance.
Sponsor: AACR
- 2010 - 2013 Immunity to Melanoma Mediated by Anti-TRP1 Antibody + Cyclophosphamide. (Saenger)
Sponsor- Dermatology Foundation
- 2006 - 2008 Funded Trainee, K12 clinical scientist training grant, MSKCC (PI Schwartz)
Sponsor- NCI, NIH
- 2004 - 2007 K30 Fellow, NIH institutional clinical research methodology training grant (PI Bajorin)
Sponsor- NCI, NIH
- 1998 - 1999 Arthritis Foundation Research Fellow, funded trainee (PI Chess)

EDUCATIONAL CONTRIBUTIONS- MENTORSHIP

-
- 2020 - present Ben Fullerton BS, Pre-Medical Student Technician, Saenger lab
- 2020 - present Samuel Wijia Huang BS, Pre-Medical Student Technician, Saenger lab
- 2020 - present Reza Djavid, Medical Student CUMC
- 2020 - present Meghan Drastal, Medical Student CUMC
- 2018 - present Lucas Barker Medical Student, CUMC
- 2018 - 2020 Megan Trager, Dermatology Fellow, Saenger and Geskin labs CUMC
- 2018 - 2020 Michael Ross Moore, medical student NYU (former technician)

2018 - 2020	Emanuelle Rizk, Medical Student Johns Hopkins (former technician)
2014 - 2019	Robyn Gartrell MD, Assistant Professor, Department of Pediatrics and Division of Hematology Oncology, CUMC TL1 Precision Medicine Fellow, KL2 Awardee, and NIH Loan Repayment Program Award Recipient (Mentor Saenger, former post-doctoral fellow)
2018 - 2020	Marc Najjar MD, Surgery Fellow CUMC
2018 - 2020	Grace Finkel, Medical Student CUMC
2017 - 2019	Jaya Pradhan MD, Research Fellow Department of Pathology, CUMC
2018 - 2019	Darius Bordbar, Medical Student CUMC
2017 - 2019	Claire-Audrey Bayan, Medical Resident Dermatology, University of Minnesota
2017 - 2018	Donian Chyong, Undergraduate Student, Columbia U
2017- 2018	Rachel Park, Undergraduate Student, Columbia U
2016 - 2019	Andrew Silverman MD, Attending Pediatric Oncologist, Hackensack Medical Center
2016 - 2018	Camden Esancy, Clinical Research Coordinator, CUMC
2015 - 2017	Thomas Enzler MD PhD, Assisat Professor, Hematology Oncology, U of Michigan
2015 - 2017	Douglas Marks MD, Director NYU Winthrop Hospital Cancer Clinical Trials Office
2015 - 2017	Kimberly Komatsubara MD, Associate Medical Director, Genentech
2015 - 2017	Danielle Davari, Medical Student, UNC, Chapel Hill
2016 - 2018	Zoe Blake, Medical Student, U of of Queensland Australia
2013 - 2015	Yichun Fu, Resident in Pediatrics, Mount Sinai Medical Center
2013 - 2014	Elle de Molle MD, Dermatologist, Dermatology Physicians of CT
2012 - 2013	Sebastian Bernardo MD, Clinical Instructor, Department of Psychiatry, NYU
2011 - 2013.	Marina Moskalenko MD Radiation Oncology Resident, U of Colorado
2010 - 2012	Sara Harcharik MD, Asst. Prof. Dermatology, Yale U, Melanoma Research Alliance and Skin Cancer Foundation Medical Student Research Awardee (Mentor= Saenger)
2009 - 2011	Shanthi Sivendran MD. Medical Oncologist, private practice, PA, Bristol Myers Squibb Fellows Research Award (Mentor=Saenger)
2009 - 2011	Michael Pan MD, Dermatologist, private practice, HI

REPORT OF CLINICAL AND PUBLIC HEALTH ACTIVITIES AND INNOVATIONS

INVESTIGATOR INITIATED CANCER IMMUNOTHERAPY RESEARCH TRIALS

2016-present	A phase I study of talimogene laherparepvec administered endoscopically in the treatment of locally advanced or metastatic pancreas cancer refractory to at least one chemotherapy regimen” Funding Source: Amgen Budget: \$650,000
2018-2020	“Cognitive effects of immunotherapy in solid tumor patients” Collaboration with Dr. Patrick Brown in Psychiatry. Funding Source: CUMC
2015-2018	PI, “A Feasibility study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients with Metastatic Melanoma” Funding Source: Merck Budget: \$450,000
2013-2014	Co- PI, In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC) A Phase II Adaptive Clinical Multicenter Study (PI- Nina Bhardwaj) Sponsor: Tisch Cancer Center. Icahn School of Medicine at Mount Sinai

INVESTIGATOR INITIATED TRANSLATIONAL RESEARCH IRB PROTOCOLS

2015- present	“Study of Immune Signatures and Biomarkers in Primary Melanoma”
2016- present	“Biospecimen Collection Protocol of Cancer Patients”
2017- present	Retrospective Analysis of Biospecimens using multiplex IF”
2018- present.	“Retrospective Analysis of Biospecimens using Nanostring”

PATENTS & INVENTIONS

PATENT

Saenger, Y, Sivendran S, and Chang, R., “Biomarker associated with risk of melanoma recurrence,” filed 2015, licensed to Omniseq in 2015

PATENT APPLICATION

Saenger Y, Gartrell R, “Combination therapy with BRAF inhibitor, anti-PD1 and Talimogene Laherparepvec” application pending 2018

PUBLICATIONS

ORIGINAL, PEER-REVIEWED RESEARCH PUBLICATIONS

- 1) Luo L, Shen R, Arora A, Orlov I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, Amos C, Ernstoff MS, Seshan VE, Cust AE, Wilmott J, Scolyer RA, Mann G, Nagore E, Funchain P, Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Ollila D, Lee JE, Fang S, Rees JR, Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, **Saenger Y**, Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C, Thomas NE, Begg CB, Berwick M; Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. *InterMEL. Pigment Cell Melanoma Res.* 2022 Jul 25. PMID: 35876628
- 2) ***Gartrell RD,ENZLER T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates SE, Chabot J, Schroppe B, Kluger M, Emond J, Rabadán R, Farber D, Remotti HE, Horowitz DP, **Saenger YM**. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma, *Oncimmunology.* 2022 May 5. PMID: 35558160
- 3) *** Gartrell R, Blake Z, Rizk EM, Perez-Lorenzo R, Weisberg SP, Simoes I, Esancy C, Fu Y, Davari DR, Barker LW, Finkel GG, Mondal M, Minns HE, Wang SW, Fullerton BT, Lozano F, Chiuzan C, Horst B, **Saenger YM**, Combination Immunotherapy Including T-Vec Creates a Favorable Tumor Immune Micro-environment in Transgenic BRAF Murine Melanoma, *Cancer Immunol Immunother* 2022 Jan 9. PMID: 34999916
- 4) Marks DK, Kucharczyk J, Kim P, Chyong DI, Gartrell RD, Lu Y, Hibshoosh H, Guo H, Evans TRJ, Lopez J, Kristeleit R, Connolly E, **Saenger Y**, Kalinsky K. Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. *Cancer Invest.* 2021 Jul-Aug;39(6-7):466-472. PMID: 34075851
- 5) ***Trager MH, Rizk E, Rose S, Zhu K, Lau B, Fullerton BT, Pradhan J, Moore M, Srivastava AC, Singer G, Gartrell R, Chang R, Geskin LJ, **Saenger YM**, Goldenberg G. Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non-responders. *Sci Rep.* 2021 Apr 22;11(1):8775. PMID: 33888854
- 6) Schutt CR, Sun H, Pradhan JS, **Saenger Y**, Ley J, Adkins D, Ingham M, Ding L, Van Tine BA. Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma. *Oncotarget.* 2021 Mar 16;12(6):534-548. PMID: 33796222
- 7) ***Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, **Saenger YM**. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. *Sci Rep.* 2021 Feb 2;11(1):2809..PMID: 33531581
- 8) Moreno-Manuel A, Jantus-Lewintre E, Simões I, Aranda F, Calabuig-Fariñas S, Carreras E, Zúñiga S, **Saenger Y**, Rosell R, Camps C, Lozano F, Sirera R. Transl. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. *Lung Cancer Res.* 2020 Aug;9(4):1074-1083. doi: 10.21037/tlcr-19-445. PMID: 32953486
- 9) ***Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, **Connolly E, Saenger Y, Kalinsky K** (co-senior authors), “Akt

- Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer,” *Front Oncol*. 2020 Jun 16;10:968. PMID: 32612958
- 10) ***Audrey-Bayan C, Trager MH, Gartrell-Corrado RD, Rizk EM, Pradhan J, Silverman AM, Lopez A, Marks DK, Niedt G, Geskin LJ, **Saenger YM**, “Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.” *Melanoma Res*. 2020 Aug;30(4):410-415. PMID: 32379409
 - 11) Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, Schwartz LH, Gómez RGH, **Saenger Y**, Robert C, Ammari S, Dercle L., “Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.” *Eur J Nucl Med Mol Imaging*. 2020 Sep;47(10):2301-2312. PMID: 32206839
 - 12) ***Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, Geskin LJ, Schwartz GK, Schwartz L, Dercle L, **Saenger YM**, “FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.” *Clin Nucl Med*. 2020 Apr;45(4):267-275 PMID: 32108700
 - 13) *** Gartrell-Corrado RD, Chen A, Rizk EM , Marks DK, Bogardus M, Hart TD, Silverman AM, Bayan CA, Finkel G, Barker L , Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A , Rabadán R, **Saenger Y**, “Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma,” *Cancer Research*. 2020 Mar 1;80(5):1078-1087. PMID: 31948941
 - 14) Weisberg SP, Carpenter DJ, Chait M, Dogra P, Gartrell-Corrado RD, Chen AX, Campbell S, Liu W, Saraf P, Snyder ME, Kubota M, Danzl NM, Schrope BA, Rabadan R, **Saenger Y**, Chen X, Farber DL. Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. *Cell Rep*. 2019 Dec 17;29(12):3916-3932. PMID: 31851923
 - 15) Acs B, Ahmed FS, Gupta S, Wong PF, Gartrell RD, Sarin Pradhan J, Rizk EM, Gould Rothberg B, **Saenger YM**, Rimm DL., “An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. *Nat Commun*. 2019 Nov 29;10(1):5440. PMID: 31784511
 - 16) ***Kulkarni PM, Robinson EJ, Pradhan JS, Gartrell-Corrado RD, Rohr B, Kluger HM, Wong PF, Acs B, Rizk EM, Yanc C, Mondal M, Moore M, Phelps R, Hoorst BA, Ferringer T, Rimm DL, Wang J, **Saenger Y**, “Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death,” *Clinical Cancer Research*. 2019 Oct 21. *Clinical Cancer Research*.1495.2019. PMID: 31636101
 - 17) Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD, Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, **Saenger Y**, Young S, Sikora AG, “Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition,” *J Immunother Cancer*. 2019 Aug 13;7(1):216 PMID: 31444598
 - 18) Mokrane F, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Marabelle A, **Saenger Y**, Rousseau H, Zhao B, Schwartz L, Dercle L, “Radiomic Machine Learning signature for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients with Indeterminate Liver Nodules,” *European Journal of Nuclear Medicine Eur Radiol*. 2019 Aug 23. PMID: 31444598
 - 19) ***Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Annari S, Moya-Plana A, Mokrane FXZ, Gartrell RD, Finkel G, Barker L, Bigorgne A, Schwartz LH, **Saenger Y**, **Robert C**, **Dercle L** (co-senior authors), “Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics,” *Eur J Nucl Med Mol Imaging*. 2019 Oct;46(11):2298-2310. PMID: 31346755
 - 20) ***Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gerard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernststoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst B, **Saenger YM**, “Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma,” *Clinical Cancer Research*, 2019 Jan 15 PMID: 30647081
 - 21) Zhao J, Chen AX, Gartrell RD, Silverman A, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Goetz M, Yagamuchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yun J, Canoll P, Bruce JN, **Saenger YM**, Sims P, Iwamoto FB, Sonabend AM, Rabadan, R. “Longitudinal genomic study of response to anti-PD-1 immunotherapy in Glioblastoma Multiforme,” *Nature Medicine* 2019 Mar 25(3):462-469 PMID: 30742119
 - 22) Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, **Saenger YM**, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG, “Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy,” *J Immunother Cancer* 2019 Jan 15;7(1):10. PMID:30646957
 - 23) Chen JC, Perez-Lorenzo R, **Saenger YM**, Drake CG, Christiano AM, “IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy,” *Cell Systems* 2018 Jul 25;7(1):92-103. PMID:29960886

- 24) Kyi C, Roudko V, Sabado R, **Saenger Y**, Loging W, Sacris E, Mandeli J, Donovan M, Posner, MR, Misiukiewicz K, Breenbaum B, Friedlander P, Bhardwaj N, Salazar AM, “Therapeutic Immune Modulation Against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial,” *Clinical Cancer Research* 2018 Jun 27. PMID: 29950349
- 25) ***Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, **Saenger YM**, “Quantitative Analysis of Immune Infiltrates in Primary Melanoma,” *Cancer Immunol Res.* 2018 Apr;6(4):481-493 PMID: 29467127
- 26) Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, **Saenger Y**, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS, “Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden,” *J Immunother Cancer.* 2018 May 9;6(1):32 PMID: 29743104
- 27) Wu CC, Chaudhary KR, Na YH, Welch D, Black PJ, Sonabend AM, Canoll P, **Saenger YM**, Wang TJC, Wu CS, Hei TK, Cheng SK.. “Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform.” *Int J Radiat Oncol Biol Phys.* 2017 Sep 1;99(1):191-201 PMID: 28816146
- 28) ***de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, **Saenger YM**. “Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.” *Cancer Immunol Immunother.* 2015 Jun 16. PMID: 26076664
- 29) ***Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, **Saenger Y**. “Requirement for Innate Immunity and CD90+ NK1.1- Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy.” *Cancer Immunol Res.* 2015 Mar;3(3):296-304.PMID: 25600438
- 30) Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, **Saenger Y**, Fu Y, Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N. “Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses.” *Cell Reports.* 2014 Dec 11;9(5):1856-70. PMID: 25466255
- 31) ***Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer T, Tismenetsky M, Tsui C, Friedlander P, Parides M, Leibold M, Banchereau J, Wolchok J, Bhardwaj N, Burakoff S, Oh WK, Palucka A, Merad M, Schadt E, **Saenger Y**, “Dissection of immune gene networks critical for anti-tumor surveillance in stage II-III resectable melanoma,” *Journal of Investigative Dermatology*, 2014 Aug;134(8):2202-11 PMID: 24522433
- 32) ***Harcharik S, Bernardo S, Moskalenko M, Pan, M, Sivendran, M, Bell H, Hall LD, Castillo-Martin, M, Fox, K Cordon-Cardo C, ChangR, Sivendran S, Phelps R, **Saenger Y**, “Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage II-III cutaneous melanoma,” *Journal of the American Academy of Dermatology*, 2014 Aug; 134(8):2202-11 PMID: 24522433
- 33) *****Saenger Y**, Magidson J, Liaw B, Wassman K, Barker W, Harcharik S, Fisher D, Oh W, Friedlander P. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab *Clinical Cancer Research* 2014 Jun 15; 20 (12):3310-8. PMID 24721645
- 34) Keenan B, **Saenger Y**, Kafrouni M, Leubner A, Lauer P, Maitra A, Rucki A, Gunderson J, Coussens L, Brockstedt D, Dubensky T, Armstrong T and Jaffee E. A *Listeria monocytogenes* vaccine targeting mutated Kras, an early genetic event in pancreas cancer development, prevents pre-malignant tumor progression *Gastroenterology* 2014 Jun; 146(7) :1784-94.e6 PMID: 24607504
- 35) ***Bernardo S, Moskalenko M, Pan M, Shah S, Sidhu H, Sicular S, Harcharik S, Chang, R, Friedlander P, **Saenger Y**, “Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma,” *Melanoma Research* 2013 23(1):47-54
- 36) Hashimoto D, Chow A, Greter M, **Saenger Y**, Kwan WH, Leboeuf M, Ginhoux F, Ochando JC, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger PS, Stanley ER, Frenette PS, Merad M, Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. *J Exp Med.* 2011 208(5):1069-82.
- 37) *****Saenger Y**, Li Y, Chan B, Chiou K, Rizzuto G, Terzulli S, Merghoub T, Houghton A, Wolchok J, Improved tumor immunity using anti-Typr-1 mAb combined with DNA vaccines in murine melanoma. *Cancer Research* 2008; 68:9884-91.

- 38) *****Saenger Y**, Wolchok J, The heterogeneity of response to ipilimumab in metastatic melanoma: patient cases. *Cancer Immunity* 2008; 8:1-7.
- 39) Chen W, Zhang L, Liang B, **Saenger Y**, Li J, Chess L, Jiang H, Perceiving the avidity of T cell activation translated into peripheral T cell regulation. *PNAS* 2007; 104:20472-7.

REVIEWS, CHAPTERS, MONOGRAPHS, EDITORIALS

- 40) Djavid AR, Stonesifer C, Fullerton BT, Wang SW, Tartaro MA, Kwinta BD, Grimes JM, Geskin LJ, **Saenger YM**. Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence. *Cancers* 2021 Sep 30;13(19):4914. doi: 10.3390/cancers13194914.PMID: 34638397.
- 41) Movassaghi M, Chung R, Anderson CB, Stein M, **Saenger Y**, Faiena I. Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. *Cancers*. 2021 Sep 23;13(19):4757. PMID: 34638243
- 42) Trager MH, Geskin LJ, **Saenger YM**, “Oncolytic Viruses for the Treatment of Metastatic Melanoma. *Curr Treat Options Oncol*. 2020 Mar 19;21(4):26. PMID: 32266483
- 43) ***Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado LD, Wong W, **Saenger YM**, “Biomarkers predictive of survival and response to immune checkpoint inhibitors (ICI) in melanoma,” *Am J Clin Dermatol*. 2019 October 9 PMID:31602560
- 44) ***Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordgar DD, **Saenger YM**, “Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy, *Hematol Oncol Clin North Am*. 2019 Jan 17. PMID: 30833001
- 45) ***Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, **Saenger YM**, “The Role of Oncolytic Viruses in the Treatment of Melanoma, “ *Curr Oncol Rep*. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3. PMID: 30145781
- 46) Blagoev KB, Ting DT, Levine H, **Saenger Y**, Tlsty TD, Sun B., “Introducing cancer convergence,” *Cancer Conver*. 2017;1(1):3. PMID: 29623955
- 47) Manji GA, Olive KP, **Saenger YM**, Oberstein P, “Current and Emerging Therapies in Metastatic Pancreatic Cancer.” *Clin Cancer Res*. 2017 Apr 1;23(7):1670-1678. PMID: 28373365
- 48) Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, **Saenger Y**. “Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers,” *Semin Oncol*. 2016 Dec 43(6):638-646. PMID: 28061981
- 49) *****Saenger Y**, de Moll E, Fu Y. “Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer.” *Oncoimmunology*. 2014 Jul 3;3(7). PMID: 25610728
- 50) Ascierto PA, Grimaldi AM, Anderson A, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi F, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, **Saenger Y**, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, “Future perspectives in melanoma research: meeting report from the “Melanoma Bridge,” Napoli,” December 5th-8th 2013. *J Transl Med*. 2014 Oct 28;12(1):277
- 51) Sivendran S, Chang R, Pham L, Phelps, R, Harcharik S, Hall L, Fu Y, Bernardo S, Moskalenko M, Sivendran M, Moon Sivendran S, Chang R, Harcharik S, Hall L, Bernardo S, Marina Moskalenko, Phelps R, Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern R, Friedlander P, Ruby C, **Saenger Y** and Kaufman, H, “Oncolytic viral therapy for cancer, *Oncolytic Virotherapy* 2013.
- 52) ***Sivendran S, Glodny B, Pan M, Merad M, **Saenger Y**, Melanoma immunotherapy. *Mt Sinai J Med*. 2010;77(6):620-42.
- 53) ***Sivendran S, Pan M, Kaufman, HL **Saenger Y**, Herpes simplex oncolytic vaccine therapy in melanoma. *Expert Opin Biol Ther*. 2010 10(7):1145-53
- 54) ***Wolchok JD, **Saenger Y**, The mechanism of anti-CTLA-4 activity and the negative regulation of T cell activation. *Oncologist* 2008; Suppl 4:2-9.
- 55) ***Wolchok J, **Saenger Y**, Current Topics in Melanoma. *Current Opinion in Oncology* 2007; 19:116-120.
- 56) *****Saenger Y**, Wolchok J, Commentary: Cytokines in Cytotherapy. *Cytotherapy* 2006; 8:313-14.

CASE REPORTS

- 57) Kang E, Martinez M, Moisaner-Joyce H, **Saenger YM**, Griesemer AD, Kato T, Yamashiro DJ, Remotti H, Gartrell RD. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. *Pediatr Transplant*. 2021 Dec 15:e14209. PMID: 34907641

- 58) Trager MH, Coley SM, Dube G, Khan S, Ingham M, Samie FH, Geskin LJ, McDonnell D, Brouder D, **Saenger Y**, Carvajal R.J Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. *Immunother Cancer*. 2020 Jun;8(1). PMID: 32503950
- 59) Yang J, Lagana SM, **Saenger YM**, Carvajal RD, “Dual checkpoint inhibitor-associated eosinophilic enteritis,” in press, *J Immunother Cancer*
- 60) ***Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst BA, **Saenger YM**, “Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition,” *J Immunother Cancer*. 2018 Apr 6;6(1):25 PMID:29622046
- 61) Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, **Saenger YM**, Gartrell RD. “Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.,” *J Immunother Cancer*. 2016 Apr 19 PMID: 27096097

INVITED AND/OR PEER-SELECTED PRESENTATIONS AT REGIONAL, NATIONAL OR INTERNATIONAL LEVELS:

ORAL PRESENTATIONS

- 2022 Invited Speaker, SITC annual meeting
- 2021 Invited Speaker, SITC annual meeting
- 2021 Invited Speaker, Science Webinars
- 2021 Invited Speaker, Melanoma Committee, ECOG
- 2021 Invited Speaker, AACR annual meeting (virtual)
- 2020 Invited Speaker, SITC annual meeting (virtual)
- 2019 Invited Speaker, Roswell Park Cancer Center Grand Rounds
- 2019 Invited Speaker, SITC Cancer Immune Responsiveness Workshop, Houston TX
- 2019 Invited Speaker, Next Generation Diagnostics Conference, Washington DC
- 2019 Invited Speaker, Eastern Cooperative Oncology Melanoma Committee Spring Meeting
- 2019 Invited Speaker, Northwestern School of Medicine Oncology Rounds
- 2019 Invited Speaker, University of Chicago Medical Oncology Rounds
- 2019 Invited Speaker, Molecular Med Tri-Con, San Francisco, CA
- 2019 Invited Speaker, FDA Intra-Lesional Cancer Therapies Symposium, Silver Spring, MD
- 2018 Invited Speaker, Melanoma Research Alliance Annual Retreat, Washington DC
- 2018 Invited Speaker, Yale Comprehensive Cancer Center Grand Rounds
- 2017 Invited Speaker, New York Genome Center Cancer Network Meeting, New York, NY
- 2017 Invited Speaker, Jax Genomic Medicine, Hartford CT
- 2017 Invited Speaker, Progress in Oncology Symposium, Kansas City Medical Center, Kansas City MO
- 2017 Invited Speaker, Society for the Immunotherapy of Cancer Annual Meeting, National Harbor MD
- 2016 Invited Speaker, Society for the Immunotherapy of Cancer, Advances in Cancer Immunotherapy Series, New York, NY
- 2016 Invited Speaker, National Science Foundation- Rice Workshop, Systems and Synthetic Biology for Designing Rational Cancer Immunotherapies. Tysons Corner VA
- 2015 Invited Speaker, New and Emerging Therapies for Melanoma CME Lecture Series (Florida, New York and Illinois)
- 2015 Invited Speaker, Department of Oncology, Roswell Park Cancer Institute
- 2014 Invited Speaker, Paris Annual Melanoma Conference
- 2014 Invited Speaker, Georgetown Annual Biomedical Informatics Symposium
- 2013 Invited Speaker, Society for the Immunotherapy of Cancer Annual Meeting
- 2013 Invited Speaker, Perspectives in Melanoma XVII
- 2013 Invited Speaker, ECOG Melanoma Committee, Biannual Meeting
- 2013 Invited Speaker, Melanoma Bridge Meeting, Naples, Italy

- 2012 Invited Speaker, American Association for Cancer Research Annual Meeting
2010 Invited Speaker, Department of Medicine, Bronx Lebanon Hospital Grand Rounds

ABSTRACT POSTER PRESENTATIONS

- 1) Bteich F, Desai K, Zhang C, McGuckin C, Yan J, Levy R, Sultana S, Leung L, Kaubisch A, Kinkhabwala M, Bellemare S, Adedimeji A, Tow C, **Saenger Y**. “Immunotherapy efficacy and tolerability in advanced hepatocellular carcinoma (HCC) in a diverse and underserved population in the United States - Importance of baseline liver function and screening,” SITC Annual Meeting, Boston MA, 2022
- 2) Sultana S, Wang S, Cooper WR, McGuckin CR, Rakhade S, Tartaro MA, Gartrell RD, Nastiuck K, Rimm DL, Geskin LJ, Messina JL, Horst B, Ferringer TC, **Saenger Y**, “Validation of CD8/CD68 Ratio as a Biomarker for Stage II-III Melanoma,” Society for Melanoma Research Annual Meeting, Edinburgh, Scotland 2022
- 3) Rizk EM, Chen A, Silverman AM, Marks DK, Rabadan R, Fuhrman K, VanSchoiack A, Liang Y, Beechem J, Saenger YM, Gartrell RD, “High density of CD68+HLA-DR- macrophages in the stroma of primary melanoma correlates with an unfavorable immune microenvironment as assessed by Digital Spatial Profiling,” AACR Annual Meeting, Atlanta GA, 2019
- 4) Chen AR, Gartrell RD, Marks DK, Hart TH, Rizk E, Monod A, Rabadan R, **Saenger Y**, “Linking transcriptomic and imaging features of the melanoma tumor microenvironment (TME).” CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference New York, NY, 2018
- 5) Gartrell RD, Marks DK, Hart TD, Lu Y, Esancy CL, Blake Z, Taback B, Horst B, **Saenger YM**, “Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma.” ASCO Annual Meeting, Chicago IL USA, 2018 Abstract #9580
- 6) Silverman A, Ingham M, Gartrell RD, Marks DK, Park HR, Hart TD, Esancy CL, Lu Y, Remotti R, Remotti HE, **Saenger YM**, Schwartz, GK; “Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC).” ASCO Annual Meeting, Chicago IL USA, 2018 Abstract #11536
- 7) Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart TD, Esancy CL, Lu Y, Hibshoosh H, Connolly E, Kalinsky K, **Saenger YM**; “Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).” ASCO Annual Meeting, Chicago IL, USA, 2018 Abstract #12057
- 8) Silverman A, Gartrell RD, Zhao J, Batool SS, Hart TD, Hasan SS, Garvin JH, Zanazzi G, Iwamoto FM, Rabadan R, Canoll P, **Saenger YM**; “Correlation of immune infiltration of cytotoxic T cells and activated microglia in glioblastoma (GBM) post anti-PD1 therapy with response.” ASCO Annual Meeting, Chicago IL, USA, 2018 Abstract #2055
- 9) Enzler T, Gartrell RD, Fazlollahi L, Remotti, Hart TD, Marks DK, Raufi A, Lu Y, Perni S, Kim P, Monsalve C, Bates SE, **Saenger YM**, Horowitz DP, “Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.” ASCO Annual Meeting, Chicago IL, USA, 2018 Abstract #4122
- 10) Komatsubara KM, Gartrell RD, Bayan CA, Pradhan JS, Hasan SS, Hart TD, Borgardus M, Lu Marks DK, Yang J, Lopez A, Chiuzan C, Horst B, Taback B, Geskin LJ, Marr BP, Schwartz GK, **Saenger YM**, Carvajal RD Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma. ASCO Annual Meeting, Chicago IL, USA, 2018 Abstract #9570
- 11) Bogardus M, Gartrell RD, Marks DK, Esancy CL, Pabla, S, Ernstoff MS, Kirkwood JM, Chang R, Taback B, Lee SJ, Krolewski J, Morrison C, **Saenger YM**; “Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.” ASCO Annual Meeting, Chicago IL, USA, 2018 Abstract #9576
- 12) Gartrell RD, Marks DK, Hart TD, Stack E, Lu Y, Esancy CL, Gerar Cd, Davari DR, Jia DR, Armenta P, White-Stern A, El Asmar M, Blake Z, Fu Y, Horst B, **Saenger YM**; “Characterizing the tumor microenvironment (TME) in primary melanomas using multiplex immunohistochemistry (mIHC).” ASCO Annual Meeting, Chicago IL, USA, 2017 Abstract #9580
- 13) Kyi C, Sabado RL, **Saenger YM**, Loging W, Donovan MJ, Lehrer D, Mandeli, JP Salazar AM, Friedlander PA, Bhardwaj N; “Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.” ASCO SITC Clinical Immunotherapy Symposium, Orlando Fla USA, 2017 Abstract #166
- 14) Kyi C, Sabado RL, **Saenger YM**, Posner MR, Donovan M, Loging W, Sacris, E Mandeli JP, Thin TH, Misiukiewicz K, Maki RG, Salazar AM, Friedlander PA, Bhardwaj N, “In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study,” ASCO Annual Meeting, Chicago IL, USA, 2016 Abstract #3086

- 15) Cheney J, Collichio F, Andtbacka RHI, Puzanov I, Glaspy J, Milhem M, Hamid O, Cranmer L, **Saenger Y**, Chen L, Kim JJ, Kaufman HL, “Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepved (T) and ipilimumab (I) vs I alone in unresected stage IIIB-IV melanoma ESMO 2016 Copenhagen, Denmark
- 16) Gartrell R, Blake Z, Simoes I, Fu Y, Saito T, Qian Y, Lu Y, **Saenger YM**, “Establishing a model for successful immunotherapy with T-Vec combined with BRAF inhibition and anti-PD-1 in genetically engineered murine melanoma,” SITC Annual Meeting, National Harbor MD, USA 2016
- 17) Sims JS, Barton SM, Gartrell R, Kadenhe-Chiweshe A, Dela Cruz F, Turk AT, Lu Y, Mazzeo CF, Kung AL, Bruce JN, **Saenger YM**, Yamashiro DJ, Connolly EP, “Profiling absopal regression in a pediatric fibrosarcoma with a novel EML4-NTRK3 fusion using immunogenomics and high-dimensional histopathology,” SITC Annual Meeting, National Harbor MD, USA 2016
- 18) Gartrell R, Marks D, Stack E, Lu Y, Izaki D, Beck K, Jia DT, Armenta P, White-Stern A, Fu4 Y, Blake Z, Kaufman HL, Taback B, Horst B, **Saenger YM**, Defining critical features of the immune microenvironment in melanoma SITC Annual Meeting, National Harbor MD, USA 2016
- 19) Miles B, Gnjjatic S, Donovan M, Genden EM, Misiukiewicz K, Krupar R, **Saenger YM**, Demicco EG, Posner MR, Andrew Gregory Sikora, “Window of opportunity trial of HPV E7 antigen-expressing *Listeria*-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.,” ASCO Annual Meeting, Chicago IL, USA, 2015 Abstract TPS6088
- 20) **Saenger YM**, Magidson J, Liaw BC, Wassmann K, Barker W, Harcharik S, Fisher D, Oh WK, Friedlander P, “Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab,” . ASCO Annual Meeting, Chicago IL, USA 2013. Abstract #9080
- 21) Sivendran S, Chang RR, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, Oh WK, Burakoff SJ, Palucka K, Merad M, **Saenger YM**; Immune gene expression in primary melanomas to predict lower risk of recurrence and death. ASCO Annual Meeting, Chicago IL, USA 2013. Abstract # 3014
- 22) Hodi SF, Amin A, **Saenger YM**, Pennock GK, Guthrie TH, Salama AK, Flaherty LE, Koon HB, David H. Lawson, Montaser F. Shaheen, Agnes Balogh, Cyril Konto, Steven O'Day CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM). ASCO Annual Meeting, Chicago IL, USA 2013. Abstract TPS9103
- 23) Weiner RS, Friedlander P, Gordon C, **Saenger Y**, Ware M, Mahmood T, Rodgers AH, Bastian G, Urien S, Morgan LR., “A first-in-humans phase I cancer clinical trial for 4-Demthyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN)” AACR Annual Meeting National Harbor MD USA, 2013 Abstract #1185
- 24) Keenan B, **Saenger Y**, Kafrouni M, Leubner A, Lauer P, Maitra A, Gunderson A, Coussens L, Armstrong T and Jaffee E., “Prevention of pancreatic intra-epithelial neoplasm progression by a *Listeria monocytogenes* vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development” AACR Cancer Immunology, Miami FL 2012 USA Abstract #PR6
- 25) Moskalenko M, Pan M, Hashimoto D, Mortha, A, Bernardo SG, Leboeuf M, Houghton A, Wolchok J, Burakoff S, Merad M, **Saenger YM**, “Therapeutic efficacy of antitumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells.” AACR Cancer Immunology, Miami FL 2012 Abstract A43